Table 2 Change in study outcomes at 15-month follow-up in the 115 included patients
From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
Outcome | Pre-treatment median (IQR) | Post-treatment median (IQR) | P value |
|---|---|---|---|
Headache days | 30 (25–30) | 15 (7–25) | < 0.001 |
Medication days | 30 (25–30) | 15 (7–25) | < 0.001 |
MIDAS score | 87.5 (42.5–123.5) | 12 (3.5–51.5) | 0.001 |
HIT-6 score | 65 (60–69) | 62 (56–65) | < 0.001 |
NRS score | 8 (7–9) | 5 (4–7) | < 0.001 |